Sign in
Not yet recruitingPhase 4

Individualized Genotype-guided Antiplatelet Therapy in Patients With Acute Coronary Syndrome

Key facts

Who runs it
Medisch Spectrum Twente
Where
Netherlands2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
Phase
Phase 4
People taking part
3,120 people, planned
Started
15 Nov 2026
Expected to end
1 Mar 2030
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Genotype guided P2Y12 therapy
  • Standard therapy group
Record updated
16 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Patients of 18 years and older, who are capable of providing informed consent and were diag-nosed with an acute coronary syndrome
  • Patients with a coronary angiography showing obstructive coronary artery disease at time of di-agnosis (or up to 30 days thereafter)
  • Patients in whom no coronary angiography is performed during the index hospitalization or the first 30 days after the ACS, need to have at least one of the following:; known history of coronary artery disease (i.e., a previous MI, PCI, or coronary artery bypass grafting (CABG)),; proven myocardial defect by cardiac imaging that matches with previous MI,; proven myocardial ischemia, or; known coronary artery atherosclerosis as previously visualized

Who cannot take part

  • Use of oral anticoagulant therapy
  • Contra-indication for standard treatment with ticagrelor
  • Major cardiac surgical, non-cardiac surgical, or major endoscopic procedure (thoracoscopic or lap-aroscopic) within the past 6 months prior to randomization or any major surgical procedure planned 6 months after randomization
  • Participation in another randomized cardiovascular device trial or randomized pharmacological trial related to antithrombotic and/or anticoagulant therapy before reaching the primary end-point
  • Known intolerance to or absolute contraindication for clopidogrel, ticagrelor, prasugrel or acetyl-salicylic acid
  • Known pregnancy, adherence to scheduled follow-up is unlikely, or life expectancy is assumed to be less than 18 months

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Rationale Patients diagnosed with acute coronary syndrome (ACS), a sudden medical emergency where blood flow to the heart is blocked, require dual antiplatelet therapy (DAPT) for 12 months to prevent dangerous blood clots to form. This typically includes the combination of aspirin and a form of P2Y12 inhibitor, a specific type of medicine that stops platelet cells to clot. Irrespective of the treatment strategy (i.e., invasive through angioplasty or conservative with medication only), the somewhat more potent P2Y12 inhibitor ticagrelor is advised over clopidogrel. Yet, clopidogrel can be considered for patients with a higher bleeding risk, as it is associated with fewer bleeding events.

Read full original descriptionShow less

Although ischemic complications (problems that happen when the heart doesn't get enough blood and oxygen) usually appear in the first 30 days after ACS diagnosis, the bleeding risks remains high through the entire period of DAPT. A de-escalation strategy (switch from ticagrelor to clopidogrel after 30 days) could theoretically reduce the number of bleeding events, without increasing the number of ischemic events. However, in 30% of the (white) European patients, there is a small change (mutation) in their genetic material. They are carriers of at least one so called CYP2C19 loss-of-function (LOF) allele, which results in a poor or intermediate processing of clopidogrel in to its active form.

Despite knowledge of these loss of function mutations, current treatment guidelines for ACS do not provide specific recommendations on individualized, genotype-based treatment (i.e. using the unique genetic code to choose the medicine that works best) with P2Y12 inhibitors. In addition, previous conducted trials on a de-escalation strategy have not led to strong recommendations, as they were too small and cautious to give definite answers.

Objective The goal of this clinical trial is to investigate whether individualized genotype-guided treatment with DAPT after ACS diagnosis is just as safe and effective as standard clinical practice.

Participants will receive:

1. Standard treatment at the discretion of the cardiologist, or 2. Genotype-guided treatment (based on the presence of a LOF allele)

Participants included in the genotype-guided group who do not carry a LOF allele will be classified as normal processors of clopidogrel, and will de-escalate after 30 days from standard therapy to clopidogrel. If patients are proven carriers of one of the LOF alleles, de-escalation will not take place and treatment will continue as previously started.

Participants will be followed for 18 months after ACS diagnosis to collect medical data and to complete questionnaires.

The 2 groups in the trial

  • Standard therapyExisting treatment, for comparison

    Dual antiplatelet therapy described at the cardiologist's discretion

    Treatment: Standard therapy group

  • Genotype based therapyTreatment being tested

    Dual antiplatelet therapy based on CYP2C19 genotype. In case of normal or ultrafast metabolizer, patient will receive Clopidogrel 30-days after acute coronary syndrome. In case of proven carrier of the loss-of-function allele, patient will continue with ticagrelor.

    Treatment: Genotype guided P2Y12 therapy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
16 November 2026